Canary Speech (Provo, UT) and Intermountain Ventures launch the first IRB-approved study using AI-driven vocal biomarkers to detect Multiple Sclerosis, aiming for earlier, non-invasive diagnosis and improved patient outcomes.
Provo, Utah - February 10, 2026
Canary Speech, the Provo, Utah-based AI health tech company known for pioneering vocal biomarker technology, has teamed up with Intermountain Ventures, the innovation arm of Intermountain Health, to launch the first IRB-approved study exploring voice-based detection of Multiple Sclerosis (MS).
The study, led by neurologist Dr. Timothy West at Intermountain Health’s Salt Lake Clinic, will analyze patient voice samples using Canary Speech’s AI algorithms to identify subtle vocal patterns linked to MS. With over 2.9 million people affected worldwide, the research could open doors to faster, non-invasive diagnostics and earlier interventions.
“Intermountain Health is leading the way in adopting innovative technologies for patient care,” said Canary Speech CEO Henry O’Connell. “This partnership brings us closer to screening for MS earlier and improving outcomes for millions of patients.”
MS diagnosis typically involves lengthy clinical evaluations, MRIs, and invasive procedures. Canary Speech’s passive listening and AI-driven vocal analysis, previously applied to Huntington’s, Alzheimer’s, and Parkinson’s, may offer a faster, accessible alternative.
The company’s patented technology underpins real-time assessments of cognitive and neurological conditions, already helping healthcare providers monitor behavioral and cognitive health in clinical settings. Canary Speech’s new study expands this approach, applying it to one of the most complex neurological diseases.
Read more about the study here.